

**Purified anti-human CD56 (NCAM) Recombinant**

**Catalog # / Size:** 2594010 / 100 µg

**Clone:** QA18A21


**Isotype:** Mouse IgG1, κ

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide

**Concentration:** 0.5 mg/mL




Human peripheral blood lymphocytes stained with purified recombinant CD56 (clone QA18A21) (left) or purified mouse IgG1, κ isotype control (right), followed by anti-mouse IgG PE and CD3 APC.

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.125 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.



Human peripheral blood lymphocytes stained with purified recombinant CD56 (clone QA18A21) (left) or purified mouse IgG1, κ isotype control (right), followed by anti-mouse IgG PE and CD16 FITC.

**Description:** CD56 is a single transmembrane glycoprotein also known as NCAM (Neural Cell Adhesion Molecule), Leu-19, or NKH1. It is a member of the Ig superfamily. The 140 kD isoform is expressed on NK cells and NK-T cells. CD56 is also expressed in the brain (cerebellum and cortex) and at neuromuscular junctions. Certain large granular lymphocyte (LGL) leukemias, small-cell lung carcinomas, neuronal derived tumors, myelomas, and myeloid leukemias also express CD56. CD56 plays a role in homophilic and heterophilic adhesion via binding to itself or heparin sulfate.

**Antigen  
References:**

1. Rosental B, et al. 2011. *J Immunol.* 187:5693. [PubMed](#)
2. Correia DV, et al. 2011. *Blood.* 118:992. [PubMed](#)
3. Schlecker E, et al. 2014. *Cancer Res.* 74:3429. [PubMed](#)
4. Snyder JM, et al. 2014. *PLoS One.* 9:e107257. [PubMed](#)
5. Siebert N, et al. 2014. *PLoS One.* 9:e107692. [PubMed](#)
6. Rider P, et al. 2015. *J Immunol.* 195:1705-12. [PubMed](#)
7. Davis ZB, et al. 2011. *J Vis Exp.* 49: 2668. [PubMed](#)
8. Robin JD, et al. 2015. *J Vis Exp.* 95: 52307. [PubMed](#)
9. Ames E, et al. 2015. *J Immunol.* 195: 4010-9. [PubMed](#)
10. Laroni A, et al. 2016. *J Autoimmun.* 72:8-18. [PubMed](#)
11. Pachnio A, et al. 2016. *PLoS Pathog.* 12:e1005832. [PubMed](#)
12. Wouters K, et al. 2017. *Sci Rep.* 7:42665. [PubMed](#)